Most biologic agents, including anti-PD-L1 monoclonal antibodies, are hindered by their inability to cross the blood–brain barrier (BBB) and the blood–tumor barrier (BTB), particularly when their molecular weight exceeds 400–600 kDa. Here, CD274 is linked to neoplasm.